Antibacterial Drugs Market Research Insights Shared in Detailed Report 2027

According to Transparency Market Research’s latest report on the global antibacterial drugs market for the historical period 2017–2018 and forecast period 2019–2027, high prevalence of infectious diseases, increase in research and developmental activities, and increase in initiatives by government in healthcare sector are the factors projected to drive the global antibacterial drugs market during the forecast period
According to the report, the global antibacterial drugs market was valued at US$ 46.37 Bn in 2018 and is anticipated to expand at a CAGR of 1.5% from 2019 to 2027

To know the scope of our report Get a Sample on Antibacterial Drugs Market

High prevalence of infectious diseases results in increasing number of patient population and rise in the demand for antibacterial drugs, which thereby is responsible for driving the antibacterial drugs market
According to Baylor College of Medicine, infectious diseases are a leading cause of death worldwide, particularly in low income countries, especially in young children.
European Centre for Disease Prevention and Control (ECDC) states that, every year, around three million people in the EU catch a healthcare-associated infection, of whom approximately 50,000 die.
According to National Hospital Ambulatory Medical Care Survey in 2016 in U.S., approximately 280,000, emergency department visits resulted in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases

Get a glimpse of the in-depth analysis through our Report Brochure

According to a study published in 2016, titled “Infection in an aging population”, the global population is rapidly aging. Currently, 566 million people are 65 years old worldwide, with estimates of nearly 1.5 billion by 2050, particularly in developing countries. Infections constitute a third of mortality in people 65 years old. Moreover, lengthening life spans correlate with increased time in hospitals or long-term care facilities and exposure to drug-resistant pathogens. Indeed, the risk of nosocomial infections increases with age, independent of duration spent in healthcare facilities.
According to WHO, antibiotic resistant bacteria are responsible for up to 60% of hospital acquired infections in the United States. Resistance means that people with infections are ill for longer periods, and are at greater risk of dying, and that disease epidemics are prolonged.
As per WHO, in 2016, around 490,000 people developed multi-drug resistant tuberculosis globally, and drug resistance is starting to complicate the fight against HIV and malaria, as well.
Therefore, rise in geriatric population, and increasing number of antibiotic resistance or multi-drug resistant bacterial strains are responsible for boosting the growth of the antibacterial drugs market

The Generic Drug User Fee Amendments (GDUFA), passed by U.S. Congress in 2012, were intended to speed U.S. Food and Drug Administration approval of new generic drugs, which create competition for brand drugs and reduce drug prices for consumers.
Wide availability of over the counter (OTC) drugs and generic drugs, and number of antibacterial drugs near to off patent is anticipated to lead to a shift from branded drugs to generic ones, which could hamper the antibacterial drugs market from realizing its true revenue potential.
Henceforth, above mentioned factors can thereby hamper the growth of the antibacterial drugs market